Aktis Oncology Inc(AKTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 43.37% | Shs Outstand | 53.5M | Perf Week | 1.27% |
| Market Cap | 0.89B | Forward P/E | - | EPS next Y | -26.15% | Insider Trans | -0.5% | Shs Float | 31.5M | Perf Month | -13.98% |
| Enterprise Value | 0.38B | PEG | - | EPS next Q | -0.46 | Inst Own | 43.75% | Short Float | 13.69% | Perf Quarter | -28.34% |
| Income | - | P/S | - | EPS this Y | 97.72% | Inst Trans | -0.67% | Short Ratio | 11.94 | Perf Half Y | -17.97% |
| Sales | - | P/B | 1.82 | EPS next 5Y | 68.48% | ROA | - | Short Interest | 4.31M | Perf YTD | -41% |
| Book/sh | 8.76 | P/C | 1.71 | EPS past 3/5Y | -47.94% - | ROE | - | 52W High | -53.41% ($34.19) | Perf Year | - |
| Cash/sh | 9.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 8.22% ($14.72) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 5.72% 5.63% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.33 | EPS Q/Q | -55.52% | Profit Margin | - | RSI (14) | 36.38 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.33 | Sales Q/Q | 133.86% | SMA20 | -4.52% ($16.68) | Beta | - | Target Price | $36 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/13 | SMA50 | -22.57% ($20.57) | Rel Volume | 0.7 | Prev Close | $16.85 |
| Employees | 79 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | -0.19% 25.44% | SMA200 | -24.2% ($21.02) | Avg Volume(3M) | 0.36M | Price | $15.93 |
| IPO | 2026/1/9 | Option/Short | Yes/Yes | Trades | 2215 | Volume | 251,549 | Change | -5.46% |
🧬 Actis Oncology (AKTS) is a clinical-stage oncology biotech developing targeted radiopharmaceuticals that deliver alpha-emitting isotopes directly to tumors. Through its proprietary miniprotein radio-conjugate platform, it pursues strong tumor binding and penetration along with rapid clearance from healthy tissue, with the goal of improving the therapeutic index. It is classified as a next-generation alpha radiopharmaceutical company aiming to expand its reach into solid tumor patient populations.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +97.7% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 43.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #169 of 597 in the industry
Based on market cap of $886M.
ALMS#166 Alumis Inc $898M PER - 
JBIO#167 Jade Biosciences Inc $894M PER - 
ANRO#168 Alto Neuroscience Inc $887M PER - AKTS#169 Aktis Oncology Inc $886M PER - 
IVA#170 Inventiva ADR $868M PER - 
FAQ
What kind of company is AKTS?
AKTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AKTS?
The market cap of AKTS is approximately $886M, ranking 2,673 within its sector.
What is the 52-week high and low for AKTS?
AKTS has recorded a 52-week high of $34.19 and a low of $14.72.
